Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2012

View Archived Issues

Researchers at Allergan prepare new S1P1 receptor ligands

TiGenix reports on phase I Cx-621 trial

Tissue Therapies provides update on CE mark application for wound-healing product

PAION receives government grant for thrombomodulin mutants

DiscoveryBioMed receives funding to support metabolic diseases drug discovery program

Safety results presented on new MedImmune immunotherapeutic

AMG-900 shows promise in first-in-human trial

Scientists discover cause of Sengers syndrome / News in Context

Navitoclax administered with bendamustine/rituximab in phase I study

Dinaciclib is highly active in phase I trial in chronic lymphocytic leukemia

ImmunoCellular Therapeutics to expand enrollment in ICT-107 trial

FDA grants priority review for ocriplasmin BLA

Alla Chem discloses novel antivirals

New agents for leukemia developed in U.S.

Novel chemokine receptor antagonists patented by Emory University

New beta-amyloid inhibitors designed in Japan

Constellation Pharmaceuticals presents new inhibitors of bromodomain-containing proteins

Biogen Idec and Isis to collaborate on myotonic dystrophy program

Ferring Pharmaceuticals gains licensing rights to IBAT inhibitor

Takeda reports novel anticancer agents

Drug discovery collaboration begins for postpartum hemorrhage

BioDelivery Sciences reports on BEMA-buprenorphine/naloxone study

Leukemia & Lymphoma Society and Celator expand partnership

CBio discloses planned merger

FDA accepts NDA for once-weekly contraceptive patch

EC decides in favor of SkyePharma product's approval for asthma

Spectrum Pharmaceuticals launches phase II lucanthone trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...